A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

The researchers are doing this study to find out if the study drug, enzalutamide, alone or combined with the study drug, mifepristone, is effective in treating advanced or metastatic androgen receptor-positive (AR+) triple negative breast cancer (TNBC) or estrogen receptor-low breast cancer (ER-low BC), and whether these study treatments work as well as standard chemotherapy with carboplatin, paclitaxel, capecitabine, or eribulin.

Trial Details

NCT ID
NCT06099769
Phase
PHASE2
Sponsor
Memorial Sloan Kettering Cancer Center
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • Enzalutamide
  • Mifepristone
  • TPC
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • San Francisco, California, United States|37.77493,-122.41942
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Basking Ridge, New Jersey, United States|40.70621,-74.54932

Key Eligibility Criteria

  • Screening Cohort (non-MSK patients only):
  • Age ≥18 years at time of consent
  • signed the pre-screening informed consent document to allow for AR testing as part of study screening
  • Treatment Cohort:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →